Cardiff Oncology, Inc. (CRDF): CMO Dr. Leila Alland appointed interim

Events in this filing

Item 5.02 as filed

Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On
October 22, 2026, Dr. Roger Sidhu, Chief Medical Officer of Cardiff Oncology, Inc. (the “Company”) separated from the Company
in connection with a mutually agreed upon transition.
On
October 23, 2026, the Company entered into an amended and restated consulting agreement with Leila Alland Md Consultancy LLC (the “Agreement”)
pursuant to which Dr. Leila Alland will serve as interim Chief Medical Officer of the Company. The Agreement shall commence on October
23, 2026 and remain in effect until the earlier of (a) April 22, 2027 or (b) the date on which all services have been completed. Thereafter,
the Agreement may be extended by mutual agreement. Dr. Alland will be paid a monthly fee of $35,000 and will devote up to fifty percent
(50%) of her professional time as Chief Medical Officer.
Dr.
Alland has served as Chief Medical Officer at several clinical-stage biotechnology companies, including PMV Pharma, a precision oncology
company focused on p53; Affimed, an immuno-oncology company; and Tarveda Therapeutics, a company developing targeted drug conjugates.
Previously, she held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to
the development and approvals of oncology therapies including Tagrisso®, Opdivo®, Tasigna® and Caelyx®. Dr. Alland currently
serves on the Board of Directors of Abeona Therapeutics.
Dr.
Alland received her medical degree from New York University and her bachelor’s degree from the University of Pennsylvania. She
completed her pediatric training at The Children’s Hospital of Philadelphia and her hematology/oncology training at Memorial Sloan
Kettering Cancer Center. She previously served on the faculty of Albert Einstein College of Medicine, where she cared for children with
cancer and conducted research focused on oncoproteins and epigenetics.
Opdivo®
is a registered trademark Bristol-Myers Squibb Company. Tagrisso® is a registered trademark of AstraZeneca PLC. Tasigna® is a
registered trademark of Novartis AG. Caelyx® is registered trademarks of Johnson & Johnson.